What You Should Know:
Culmination Bio, a data and technology company combining clinical and biospecimen data, announced a partnership with BillionToOne, Inc., a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all.Culmination Bio and BillionToOne are working together to leverage their respective strengths in order to facilitate the development and validation of robust and impactful oncology
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Manifold Secures $15M to Revolutionize Clinical Research with AI
What You Should Know:
- Manifold, an AI-powered clinical research platform raises $15M in a Series A funding round led by TQ Ventures with participation from Calibrate Ventures, SK Ventures, and existing investors TTCER Partners and Dr. Sachin H. Jain.
- By accelerating research progress, Manifold paves the way for faster development of life-saving treatments and improved patient outcomes.
AI-Powered Clinical Research Platform
Manifold tackles a critical challenge in medical
Read More
myTomorrows Partners with brainstrust to Support Brain Cancer Patients in Accessing Clinical Trials
What You Should Know:
myTomorrows, a global health technology company connecting patients with all possible treatment options, today announced a new partnership with brainstrust, a UK-based charity that helps people living with a brain tumor reach their potential and thrive.Under the new partnership, people with brain tumors will be equipped with the means to bolster their knowledge of relevant treatment options, potentially extending to participation in clinical trials and access to
Read More
Nucleai Secures $14M to Enhance Clinical Trial Enrollment with Spatial AI Biomarker
What You Should Know:
- Nucleai, a pioneer in spatial AI biomarkers raises $14M in funding led by M Ventures, the corporate venture arm of Merck KGaA.
- The investment brings Nucleai's total funding to $60M and fuels their mission to transform personalized medicine through AI-powered patient selection for clinical trials.
AI-Driven Spatial Biomarkers
Nucleai's groundbreaking technology deciphers the intricate conversations between cells within tissue samples. By leveraging AI and
Read More
Verix Adds Gen AI Database Explorer to Commercial Pharma Optimization
What You Should Know:
- Verix, a leader in AI-powered commercial operations solutions for the pharmaceutical industry, has announced the launch of its revolutionary GenAI Database Explorer.
- The GenAI-powered tool empowers sales reps with the ability to explore complex commercial data using natural language processing (NLP), marking a significant step forward in data accessibility and insights generation.
Empowering Sales Teams with Natural Language Queries
Verix's flagship
Read More
Pharmacovigilance in Crisis: Automation as the Answer to Workforce Shortages
The healthcare industry is no stranger to workforce shortages, and the pharmaceutical industry may be next to experience disruptions brought on by labor challenges. According to the U.S. Bureau of Labor Statistics, it is estimated that occupations across life, physical and social sciences are expected to grow 7% by 2028. However, statistics also indicate that about 136,800 openings in these fields will remain unfilled annually through 2032, as employment growth and worker resignations are
Read More
Chan Zuckerberg Initiative Forms AI Advisory Group & Residency Program to Develop Virtual Cell Models
What You Should Know:
- The Chan Zuckerberg Initiative (CZI) announced the formation of a powerful AI Advisory Group and an in-house AI residency program, both focused on building predictive models of healthy and diseased cells – a key step towards creating virtual cell models.
AI Advisory Group Background & Members
CZI's newly established AI Advisory Group will provide invaluable guidance and cross-disciplinary insights to CZI and the Chan Zuckerberg Biohub Network to push the
Read More
Cybin Raises $150M to Advance Psychedelic Therapy for Depression
What You Should Know:
- Cybin Inc. (NYSE American: CYBN), a company developing next-generation psychedelic therapies for mental health, has secured $150M in a private placement of common shares led by Deep Track Capital and included participation from other institutional investors. The price per share was set at $0.43, representing a 17% premium over the 10-day volume-weighted average trading price.
- The funding will fuel the development of CYB003, a potential first-in-class psychedelic
Read More
AstraZeneca Acquires Fusion Pharmaceuticals for $2B to Bolster Radioconjugate Pipeline
What You Should Know:
AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments.
AstraZeneca's Acquisition of Fusion:
Read More
Komodo Launches Self-Service App for Pharma Research
What You Should Know:
Today, Komodo Health unveiled a new self-service solution for rapid patient cohort analysis and insight generation.MapView is the industry’s first and most sophisticated analytics application that allows users without data science expertise to easily extract insights from Komodo’s Healthcare Map. MapView is designed to accelerate decision-making across the Life Sciences enterprise by generating powerful, automated business intelligence for every team and
Read More
